Amyotrophic Lateral Sclerosis (ALS) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034

Amyotrophic Lateral Sclerosis (ALS) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034

The 7 major Amyotrophic Lateral Sclerosis (ALS) markets reached a value of US$ 494.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 715.4 Million by 2034, exhibiting a growth rate (CAGR) of 3.4% during 2024-2034.

Amyotrophic Lateral Sclerosis (ALS) market is currently driven by factors such as a rising geriatric population, a strong drug pipeline that have a good efficacy and safety profile and improving diagnosis and drug treatment rates. Amyotrophic lateral sclerosis is a rare neurological disorder that predominantly affects the nerve cells (neurons) responsible for controlling voluntary muscle movement. Although the indication can happen at any age, symptoms most commonly appear during the ages of 55 and 75. With the geriatric population expected to increase significantly over the long term, we expect the incidence of Amyotrophic Lateral Sclerosis to increase significantly over the next few years.

ALS belongs to a broader group of disorders known as motor neuron diseases, that are caused due to the gradual deterioration (degeneration) and death of motor neurons. Motor neurons are nerve cells that extend throughout the body from the brain to the spinal cord and to muscles. As motor neurons deteriorate, they cease sending messages to the muscles. As a result, the muscles gradually weaken, start to twitch, and waste away (atrophy). Eventually, this results in the brain losing its ability to initiate and control voluntary movements. Early symptoms of ALS normally include muscle weakness or stiffness. Gradually all voluntary muscles are affected, and patients lose their strength and the ability to speak, eat, move, and even breathe. The indication is progressive, resulting in the symptoms getting worse over time.

IMARC Group’s new report "Amyotrophic Lateral Sclerosis (ALS) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Amyotrophic Lateral Sclerosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The report provides an in-depth understanding of the current and future landscape of the Amyotrophic Lateral Sclerosis market. This includes treatment practices, in-market, and pipeline drugs, the share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Amyotrophic Lateral Sclerosis across the seven major markets. According to the report, among the seven major markets, the United States has the largest patient pool for Amyotrophic Lateral Sclerosis and represents the largest market for Amyotrophic Lateral Sclerosis treatment. Furthermore, the current Amyotrophic Lateral Sclerosis treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Amyotrophic Lateral Sclerosis market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, Current, and Future Epidemiology Scenario
Historical, Current, and Future Performance of the Amyotrophic Lateral Sclerosis Market
Historical, Current, and Future Performance of Various Therapeutic Categories in the Amyotrophic Lateral Sclerosis Market
Sales of Various Drugs Across the Amyotrophic Lateral Sclerosis Market
Reimbursement Scenario in the Amyotrophic Lateral Sclerosis Market
Competitive Landscape:
This report also provides a detailed analysis of the current Amyotrophic Lateral Sclerosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights

How has the Amyotrophic Lateral Sclerosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?
What was the country-wise size of the Amyotrophic Lateral Sclerosis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Amyotrophic Lateral Sclerosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the Amyotrophic Lateral Sclerosis market?


Epidemiology Insights

What is the size of the Amyotrophic Lateral Sclerosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) of Amyotrophic Lateral Sclerosis across the seven major markets?
What are the key factors driving the epidemiological trend of Amyotrophic Lateral Sclerosis?
What will be the growth rate of Amyotrophic Lateral Sclerosis patients across the seven major markets?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

What are the current marketed Amyotrophic Lateral Sclerosis drugs and what are their market performance?
What are the key pipeline Amyotrophic Lateral Sclerosis drugs and how are they expected to perform in the coming years?
How safe are the currently marketed Amyotrophic Lateral Sclerosis drugs and what are their efficacies?
How safe are the late-stage pipeline Amyotrophic Lateral Sclerosis drugs and what are their efficacies?
What are the current treatment guidelines for Amyotrophic Lateral Sclerosis drugs across the seven major markets?
Who are the key companies in the Amyotrophic Lateral Sclerosis market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Amyotrophic Lateral Sclerosis market?